1
WHAT IS YOUR PROGRAM’S CAPABILITY WITH CO-OCCURRING
DISORDERS?: An introduction to the DDCAT
(& DDCMHT)
2009 MARRCH Conference
22 October 2009
NIDA, SAMHSA & THE ROBERT WOOD JOHNSON FOUNDATION SUBSTANCE ABUSE POLICY RESEARCH PROGRAM
WHY FOCUS ON CO-OCCURRING DISORDERS?
1. Substance use disorders are common in people with mental health disorders
2. Mental health disorders are common in people with substance use disorders
3. Co-occurring disorders lead to worse outcomes and higher costs than single disorders
4. Evidence-based models exist and can be implemented 5. Providers and consumers want a better system and
services 6. Few (<10%) people get the treatments they need.
COMORBIDITY OF SUBSTANCE USE AND SPECIFIC AXIS I PSYCHIATRIC DISORDERS
Any Substance
Alcohol Diagnosis
Other Drug Diagnosis
Schizophrenia 47% 4.6 33.7% 3.3 27.5% 6.2
ASPD 83.6% 29.6 73.6% 21.0 42% 13.4
Anxiety disorders 23.7% 1.7 17.9% 1.5 11.9% 2.5
Phobia 22.9% 1.6 17.3% 1.4 11.2% 2.2
Panic disorder 35.8% 2.9 28.7% 2.6 16.7% 3.2
OCD 32.8% 2.5 24% 2.1 18.4% 3.7
Bipolar Disorder 60.7% 7.9 46.2% 5.6 40.7% 11.1
Major depression 27.2% 1.9 16.5%* 1.3 18% 3.8
Cocaine 76.1% (11.3)
Barbiturates 74.7% (10.8)
Hallucinogens 69.2% (8.0)
Opiates 65.2% (6.7)
Alcohol 36.6% (2.3)
LIFETIME RISK OF ANY MENTAL HEALTH DISORDER BY SUBSTANCE USE DISORDER
WHY DO WE NEED TO MEASURE CO-OCCURRING CAPABILITY?
1. Generic terms “integrated” or “enhanced” are “feel good” rhetoric but lack specificity. 2. Systems and providers seek guidance, objective criteria and benchmarks for providing
the best possible services. 3. Patients and families should be informed about the range of services, to express preferences and make educated treatment decisions.
4. Change efforts can be focused and outcomes of these initiatives assessed.
2
SPECIFIC AIMS
1. To develop an index that can objectively determine the dual diagnosis capability of addiction treatment services.
3. To develop practical operational benchmarks on key dimensions, and to determine if changes can be made & measured.
3. To identify change strategies that are particularly effective for enhancing the dual diagnosis capability of addiction treatment services
DDCAT INDEX: DEVELOPMENT
• Practical program level policy, practice and workforce benchmarks: Based on scientific literature and expert consensus
• Observational methodology: Interviews; Document review; Social, environmental & cultural ethnography (vs. self-report)
• Iterative process of measure refinement: Field testing and psychometric analyses
• Materials: Index, manual, toolkit & Excel workbook for scoring and graphic profiles
IS THERE A CONCEPTUAL MODEL THAT COULD GUIDE RESEARCH AND PRACTICE
FOR ADDICTION TREATMENT?
• The American Society of Addiction Medicine (ASAM) Patient Placement Criteria Second Edition Revised (PPC-2R) outlined the framework for a model
• The ASAM-PPC-2R is designed for addiction treatment services
• The ASAM-PPC-2R patient placement criteria have been widely adopted in public and private community addiction treatment
ASAM TAXONOMY OF DUAL DIAGNOSIS SERVICES
(ASAM, 2001)
• ADDICTION ONLY SERVICES (AOS)
• DUAL DIAGNOSIS CAPABLE (DDC)
• DUAL DIAGNOSIS ENHANCED (DDE)
ADDICTION ONLY SERVICES (AOS)
Programs that either by choice or for lack of
resources, cannot accommodate patients
who have psychiatric illnesses that require
ongoing treatment, however stable the
illness and however well-functioning the
patient.
DUAL DIAGNOSIS CAPABLE (DDC)
Programs that have a primary focus on the
treatment of substance-related disorders, but are
also capable of treating patients who have
relatively stable diagnostic or sub-diagnostic co-
occurring mental health problems related to an
emotional, behavioral or cognitive disorder.
3
DUAL DIAGNOSIS ENHANCED (DDE)
Programs that are designed to treat patients
who have more unstable or disabling co-
occurring mental disorders in addition to their
substance-related disorders.
DETERMINING DUAL DIAGNOSIS CAPABILITY BY ADDICTION TREATMENT
PROVIDER SURVEY
Addiction Only Services (AOS) 97 (23.0%)
Dual Diagnosis Capable (DDC) 275 (65.3%)
Dual Diagnosis Enhanced (DDE) 49 (11.6%)
(n=453)(McGovern et al, 2006b)
ASAM DUAL-DIAGNOSIS TAXONOMY SURVEY IS USEFUL BUT
MAY HAVE ACCURACY PROBLEMS
• 92.9% of sample responded to item (421/453)
• No differences in categories by professional role: Agency Directors vs. Clinical Supervisors vs. Clinicians
• Modest agreement among staff within programs: 47.3% • Survey method is rapid and economical:
Provides initial data (screening) • Survey method may have bias and error (ambiguity)
THE NEED FOR A MORE OBJECTIVE ASSESSMENT OF
ADDICTION TREATMENT SERVICES’ DUAL DIAGNOSIS CAPABILITY
• ASAM offers the road map, but no operational definitions for categories or services
• Fidelity: Adherence to an evidence-based practice or model
• Fidelity scales: Objective ratings of adherence in mental health services research
• Can we apply fidelity scale methods to estimate dual diagnosis capability?
APPLYING THE FIDELITY SCALE METHODOLOGY FOR A
MORE OBJECTIVE ASSESSMENT OF DUAL DIAGNOSIS CAPABILITY
• Site visit (yields data beyond self-report)
• Multiple sources: • 1) Documents and materials • 2) Ethnographic observation
3) Interviews with staff and patients • Unit of analysis: Program
• “Triangulation” of data
DUAL DIAGNOSIS CAPABILITY IN ADDICTION TREATMENT (DDCAT) INDEX:
DEVELOPMENT & FEASIBILITY
• Index (instrument) construction • Feedback from experts in dual-diagnosis
treatment and research, state agency administrators, addiction treatment providers, and fidelity measure experts
• Field testing the DDCAT index 1.0 (2003) • Site visits in programs • Found to be doable, useful information for
providers and psychometrically sound
4
DDCAT PSYCHOMETIC PROPERTIES
Reliability • Median alpha = .81 (Range .73 to .93) • Inter-rater reliability (MO): .76 • Inter-rater reliability (LA): .84 • Kappa (MO) = .67 (median) • Sensitivity to change (CT): p < .05 @ 9 months
Validity • Correlation with IDDT Fidelity Scale: Median = .69 (.38 to .82) • Relationship with psychiatric severity levels at admission:
Increasing access for persons with co-occurring disorder from AOS to DDC to DDE level programs (p<.001)
(Gotham et al, 2004; McGovern et al, 2006, 2007; Brown & Comaty, 2007)
DUAL DIAGNOSIS CAPABILITY IN MENTAL HEALTH TREATMENT (DDCMHT) INDEX
• Designed by Drs. Heather Gotham, Jessica Brown & Joseph Comaty as companion to DDCAT but for use in mental health programs.
• Common metric and method: 35 items, 7 dimensions, programs categorized as Mental Health Only Services (MHOS), DDC or DDE
• More likely presentation of QIII patients in mental health system (than addiction treatment system)
• Makes comparisons between systems possible
DUAL DIAGNOSIS CAPABILITY IN MENTAL HEALTH TREATMENT (DDCMHT) INDEX
• Focus on substance use capable services within a mental health program
• Compares with the Integrated Dual Disorder Treatment model (IDDT) and fidelity scale (which focus on specialized team within a program/agency)
• Less data are presently available • Being used in statewide change initiatives in
Louisiana, Missouri, New York and Vermont
DDCAT & DDCMHT (3.2): 7 DIMENSIONS & CONTENT OF 35 ITEMS
Dimension Content of items
I Program Structure Program mission, structure and financing, format for delivery of mental health or addiction services.
II Program Milieu Physical, social and cultural environment for persons with psychiatric or substance use problems.
III Clinical Process: Assessment
Processes for access and entry into services, screening, assessment & diagnosis.
IV Clinical Process: Treatment
Processes for treatment including pharmacological and psychosocial evidence-based formats.
V Continuity of Care Discharge and continuity for both substance use and psychiatric services, peer recovery supports.
VI Staffing Presence, role and integration of staff with mental health and/or addiction expertise, supervision process
VII Training Proportion of staff trained and program’s training strategy for co-occurring disorder issues.
DDCAT/DDCMHT INDEX RATINGS
1 - Addiction Only Services(AOS) or Mental Health Only Services (MHOS) 2 -
3 - Dual Diagnosis Capable (DDC) 4 - 5 - Dual Diagnosis Enhanced (DDE)
DDCAT/DDCMHT DATA COLLECTION: SOURCE, DIMENSION & TIME ALLOCATION
• Meet with agency leadership (I, VI, VII)(30’)
• Tour of program (II, III)(30’) • Meet with clinicians and other staff (III-VI)(30’) • Meet with patients (II, V)(30’)
• Observe clinical interaction or team meetings when possible (II-V)(30’)
• Review documents including medical records, brochures, program schedules, any patient/family handouts, policy & procedure manual (I-V)(60’)
5
I. PROGRAM STRUCTURE
I.A. Primary treatment focus as stated in mission statement
DDCAT: Is the stated focus addiction only, primarily addiction (with an acknowledgement of psychiatric problems) or dual diagnosis?
DDCMHT:
Is the stated focus mental health only, primarily mental health (with acknowledgement of substance use problems) or dual diagnosis?
I. PROGRAM STRUCTURE
I.B. Organizational certification and licensure
What does licensure/certification permit? Are there impediments to providing certain types
of services?
Are these impediments real?
I. PROGRAM STRUCTURE
I.C. Co-ordination and collaboration with mental health or addiction services
DDCAT: How & where are psychiatric services provided? Through relationships or integrated? Are these relationships formalized & documented?
DDCMHT:
How & where are addiction treatments provided? Through relationships or integrated? Are these relationships formalized & documented?
I. PROGRAM STRUCTURE
I.D. Financial incentives.
How do billing structures limit or incentivize services for persons with addiction and/or
psychiatric disorders?
II. PROGRAM MILIEU
II.A. Routine expectation of and welcome to treatment for both
disorders.
What patients are expected and welcomed? How is this reflected in agency documents?
II. PROGRAM MILIEU
II.B. Display and distribution of literature and patient educational materials.
What kind of information is posted on walls, on display in waiting areas, and included in patient
& family handouts and printed materials?
6
III. CLINICAL PROCESS: ASSESSMENT
III.A. Routine screening methods for psychiatric or substance use symptoms
DDCAT:
Are there routines or systems to screen for psychiatric problems? Are screening instruments used?
Are procedures systematic?
DDCMHT: Are there routines or systems to screen for substance use problems? Are screening instruments used? Are toxicological data gathered?
III. CLINICAL PROCESS: ASSESSMENT
III.B. Routine assessment if screened positive for
psychiatric symptoms
If a patient screens positive, are more detailed assessments triggered?
Are these assessments formalized & integrated?
III. CLINICAL PROCESS: ASSESSMENT
III.C. Psychiatric and substance use diagnoses made and
documented
If assessments are conducted, are psychiatric diagnoses made in addition to the substance use disorder?
Are substance use disorder diagnoses made in addition to the psychiatric disorder?
III. CLINICAL PROCESS: ASSESSMENT
III.D. Psychiatric and substance use history reflected in
medical record.
Are the chronologies and treatment course of disorders gathered (and recorded)?
III. CLINICAL PROCESS: ASSESSMENT
III.E. Program acceptance based on symptom acuity: Low, moderate, high
DDCAT:
What happens to patients who call or present for services with stable psychiatric symptoms? Or, unstable ones?
DDCMHT: What happens to patients who call or present for services with substance use in remission? Or, active substance use or intoxication? of addiction treatment?
III. CLINICAL PROCESS: ASSESSMENT
III.F. Program acceptance based on severity and persistence of disability:
Low, moderate, high
DDCAT:
What happens to patients with histories or records of severe and persistent psychiatric problems? Severe mental illness?
DDCMHT: What happens to patients with histories or records of severe substance dependence, and repeated patterns of compulsive use?
7
III. CLINICAL PROCESS: ASSESSMENT
III.G. Stage-wise assessment
Is stage of motivation assessed and documented? Is motivation to change and to use treatment
assessed for both substance use and mental health problems?
IV. CLINICAL PROCESS: TREATMENT
IV.A. Treatment plans
Do treatment plans show an equivalent and integrated focus on both substance use and
psychiatric disorders, or do they primarily focus on substance use (DDCAT) or
psychiatric (DDCMHT) issues only?
IV. CLINICAL PROCESS: TREATMENT
IV.B. Assess and monitor interactive courses of both disorders.
Are changes and/or progress with status and symptoms of both psychiatric
and substance use disorders followed
(and noted)?
IV. CLINICAL PROCESS: TREATMENT
IV.C. Procedures for psychiatric or substance use emergencies and
crisis management
Are there definite protocols for psychiatric or substance use crises
and/or those at high-risk?
IV. CLINICAL PROCESS: TREATMENT
IV.D. Stage-wise treatment
Is stage of motivation assessed on an ongoing basis? Can treatment be revised based upon changes in
motivation? Are assessments and treatments focused on differential
stages in patient motivation to change (and get help with) both mental health and
substance use problems?
IV. CLINICAL PROCESS: TREATMENT
IV.E. Policies and procedures for medication evaluation,
management, monitoring and compliance
Are medications acceptable? Are certain medications unacceptable? Are medications routine & integrated?
Are psychiatric and/or addiction medications available?
8
IV. CLINICAL PROCESS: TREATMENT
IV.F. Specialized interventions with mental health (DDCAT) or addiction
(DDCMHT) content
DDCAT: Are therapies available that focus on addiction only, generic psychological concerns, or focused on specific psychiatric disorders
(in addition to substance use treatments)?
DDCMHT: Are therapies available that focus on mental health only, generic lifestyle or behavioral concerns or on specific substance use disorders?
IV. CLINICAL PROCESS: TREATMENT
IV.G. Education about co-occurring psychiatric disorder and or substance use and
integrated treatment
Is information available on how substance use impacts a psychiatric disorder and vice versa? Is
information available about how co-occurring disorders affect treatment and recovery?
IV. CLINICAL PROCESS: TREATMENT
IV.H. Family education and support
Are family members provided information on how substance use impacts a
psychiatric disorder and vice versa? What kind of support is available for
families on these issues?
IV. CLINICAL PROCESS: TREATMENT
IV.I. Specialized interventions to facilitate use of peer support
groups in planning or during treatment
In facilitating the connection to peer recovery support groups,
how are psychiatric disorders considered? How are substance use disorders considered?
Are specialized introductions available?
IV. CLINICAL PROCESS: TREATMENT
IV.J. Availability of peer recovery supports for patients with CODs
Are peer supports and role models available for patients with co-occurring substance use and
psychiatric disorders? If so, are they on or off site, integrated with
programming?
V. CONTINUITY OF CARE
V.A. Co-occurring disorder addressed in discharge
planning process
Is recovery from both psychiatric and substance use disorders
considered when developing a discharge plan?
9
V. CONTINUITY OF CARE
V.B. Capacity to maintain treatment continuity
How is treatment terminated or continued?
Is this equivalent for both addiction and psychiatric disorders?
V. CONTINUITY OF CARE
V.C. Focus on ongoing recovery issues for both disorders
Are the disorders seen as acute or chronic, short-term or long-term, primary or secondary?
How is recovery envisioned and planned?
V. CONTINUITY OF CARE
V.D. Facilitation of peer support groups for COD is documented and a focus in discharge planning, and
connections are insured to community peer recovery support groups.
Is the potential increased peer support group linkage difficulty for the person with a psychiatric disorder
anticipated and planned for? How is it dealt with?
V. CONTINUITY OF CARE
V.E. Sufficient supply and compliance plan for
medications is documented
How is the need for continued prescribing and medication supply dealt with?
Are both psychiatric and addiction medications made available?
VI. STAFFING
VI.A. Psychiatrist or other physician or prescriber of psychotropic (DDCAT) or addiction (DDCMHT) medications
What is the relationship with a psychiatrist, physician, or nurse practitioner
(or other licensed prescribers)?
VI. STAFFING
VI.B. On site clinical staff members with mental health (DDCAT) or
drug and alcohol (DDCMHT) licensure or competency
Are any staff licensed to provide mental health services?
Addiction services? Co-occurring services?
What percentage of all staff?
10
VI. STAFFING
VI.C. Access to mental health (DDCAT) or addiction (DDCMHT)
supervision or consultation
What is the arrangement for mental health or addiction treatment supervision and/or consultation for
non-licensed staff?
VI. STAFFING
VI.D. Case review, staffing or utilization review procedures emphasize and support COD
treatment.
Is there a protocol to review the progress or process of treatments for psychiatric and substance use disorders?
VI. STAFFING
VI.E. Peer/Alumni supports are available with co-occurring
disorders
Are role models available for persons with co-occurring addiction and psychiatric disorders?
VII. TRAINING
VII.A. Direct care staff members have basic training in prevalence, common signs & symptoms, screening and assessment for
psychiatric symptoms and disorders (DDCAT) and substance use symptoms
and disorders (DDCMHT).
Who has basic training in screening & assessment?
Is training documented?
VII. TRAINING
VII.B. Direct care staff are cross-trained in mental health and substance use disorders,
including pharmacotherapies & have specialized training in treatment of persons with COD.
Who is trained?
Is staff training guided and monitored? What percentage of all staff?
DDCAT/DDCMHT EXCEL WORKBOOK: SUMS & AVERAGES SCORES,
GRAPHIC PROFILE
• Complete “face” page of Excel workbook • Transfer scores from rating scale onto Excel
workbook scoring page (no need to calculate dimension averages)
• Review dimension averages and program categorization: AOS/MHOS, DDC or DDE
• Review DDCAT/DDCMHT profile line graph
11
DDCAT/DDCMHT INDEX: SUMMARY & FEEDBACK
• Parallel process to clinical interaction: In both respect and tone MI/MET like
• Assessing organizational stage/targets of change • Affirmation of strengths • Elicit concerns and/or areas of potential growth and
perceived barriers • Discuss potential strategies for enhancement • Format: Verbal and/or written (Integrative summary
letter and graphic profile)
AOS/MHOS
DDC
DDE
DDCAT/DDCMHT PROFILE: PRACTICAL GUIDANCE FOR PROVIDERS
DDCAT/DDCMHT INDEX: PROVIDER EXPERIENCES
• Very positive • Appreciate concrete suggestions about potential
enhancement of services • Requests for specific information: training,
screening measures, evidence-based treatments • Verification of real financial constraints • Curiosity about other programs, states • Interest in measuring change over time • Value use of graphic DDCAT/DDCMHT profiles
DDCAT/DDCMHT INDEXES: SELF-ADMINISTERED FORMATS
• Several efforts to utilize DDCAT index as self-administered measure: Economic, practical, less intensive resource issue
• Balancing accuracy with practicality • Projects underway in: MA, NJ, Australia, IN • Comparison data available only for the
Australian sample, and previous research in CT
DDCAT: SELF VS. INDEPENDENT RATINGS (n=14 agencies in Australia)
USING THE DDCAT/DDCMHT TO GUIDE AND MEASURE CHANGE
• Use of the DDCAT/DDCMHT as assessment method at baseline and as a measure of change over time.
• Formal implementation and change plan development
• Co-Occurring State Incentive Grant (COSIG) initiatives
• Private non-profit agencies: CQI process • Use within NIATx change process
12
AOS
DDC
DDE
DDCAT PROFILE: An Outpatient Program in Baton Rouge
DDCAT/DDCMHT PROFILE CASE STUDY: UNDERACHIEVING PROGRAM
DDCAT/DDCMHT PROFILE CASE STUDY: OVERACHIEVING PROGRAM
DDCAT PROFILES: 3 programs within a single agency
DDE
DDC
AOS
CLINICAL AND PROGRAMMATIC STAGES OF CHANGE:
PARALLEL PROCESSES
CLINICAL CHANGE PROCESS
PROGRAM CHANGE PROCESS
Screening & Assessment Screening & Assessment
Treatment or
Recovery Plan
Implementation or Change Plan
Outcomes Outcomes
Relapse Prevention Monitoring and Sustainability
DEVELOPING A PROGRAM IMPLEMENTATION OR
CHANGE PLAN USING DDCAT/DDCMHT DATA
1. Identify the DDCAT/DDCMHT dimension (Goal)
2. Identify the DDCAT/DDCMHT item(s) (Objectives) 3. Identify the “Intervention” 4. Identify the responsible persons
5. Identify the Target Date 6. Identify Measurable Outcomes
13
DRAFT IMPLEMENTATION PLAN FOR THE BATON ROUGE PROGRAM
D GOAL OBJECTIVE
II Program
Milieu
Make milieu more welcoming; Provide handouts to patients, families; Change some items on walls.
IV Clinical:
Treatment
Develop educational group for patients on common psychiatric disorders, include segment in family night.
VII Training Get all existing staff basic training in COD issues; Add to new staff in-service orientation.
DDE
DDC
AOS
DDCAT PROFILES OVER TIME: DEPICTING PROGRAM CHANGE
STATEWIDE DDCAT/DDCMHT CHANGE
RWJ FUNDED MULTI-STATE LEARNING COLLABORATIVE
• Purpose: To learn from one another’s experience and efforts to improve services for persons with co-occurring disorders (policy, practice & workforce); Most have in common the use of DDCAT/DDCMHT measures
• Data sharing agreement; Combined data set (9 states) • 13 “official” member states (+ LA County);
10 active (+LA County) • One face-to-face meeting (2007); Monthly conference calls
since • Focus varies: Measure specific issues; successful and
unsuccessful projects; sustainability questions
COLLABORATIVE DATABASE: ADDICTION TREATMENT PROGRAMS (n=170)
Level of Care N (%)
Outpatient 45 (26%)
Intensive Outpatient 46 (27%)
Residential 70 (41%)
Inpatient 1 (1%)
Methadone Maintenance 8 (5%)
14
COLLABORATIVE : MENTAL HEALTH TREATMENT PROGRAMS
(n=58)
Level of Care N (%)
Outpatient 53 (91%)
Partial Hospitalization 3 (5%)
Inpatient 2 (4%)
9 STATE BASELINE DDCAT SUMMARY CATEGORIES (n=170)
5 STATE BASELINE DDCMHT SUMMARY CATEGORIES (n=58)
DDCAT/DDCMHT BASELINE PROGRAM CATEGORIES
DDCAT/DDCMHT PROGRAM CATEGORIES: BASELINE AND 9-12 MONTH FOLLOW-UP DDCAT CHANGES BY DIMENSION (n=71)
Baseline Follow-up t-value
Dimensions Mean (sd) Mean (sd)
I. Program Structure 2.66 (1.06) 3.13 (0.95) -5.48***
II. Program Milieu 2.68 (0.56) 3.30 (0.75) -8.99***
III. Assessment 2.78 (0.65) 3.22 (0.65) -9.07***
IV. Treatment 2.35 (0.56) 2.72 (0.57) -7.83***
V. Continuity of care 2.61 (0.79) 2.97 (0.85) -5.63***
VI. Staffing 2.90 (0.82) 3.21 (0.85) -5.31***
VII. Training 2.30 (0.74) 2.78 (0.81) -5.20***
Overall 2.61 (0.61) 3.04 (0.64) -10.98***
***p<.001
15
DDCMHT CHANGES BY DIMENSION (n=45)
Baseline Follow-up t-value
Dimensions Mean (sd) Mean (sd)
I. Program Structure 2.73 (1.00) 3.52 (0.98) -5.16***
II. Program Milieu 2.88 (0.85) 3.82 (0.72) -8.56***
III. Assessment 2.78 (0.47) 3.47 (0.47) -8.21***
IV. Treatment 2.12 (0.45) 2.72 (0.50) -9.10***
V. Continuity of care 2.30 (0.78) 2.86 (0.56) -6.24***
VI. Staffing 2.50 (0.64) 3.22 (0.70) -7.70***
VII. Training 2.23 (0.60) 2.96 (0.88) -6.15***
Overall 2.51 (0.55) 3.22 (0.56) -9.17***
***p<.001
NEXT STEPS
• Consider using the DDCAT or DDCMHT to assess your treatment services
• Most valid if program is assessed by “independent and objective” person(s)
• Options: Reciprocate with other programs (Louisiana model), state agency (Minnesota?) or outside consultant
• Use information to plan, guide and measure change
RESOURCES
• DDCAT Toolkit http://dms.dartmouth.edu/prc/dual/pdf/ddcat_toolkit.pdf
Operational definitions for all 35 DDCAT benchmarks and specific suggestions, with real examples, of how to move from AOS to DDC or DDC to DDE scores
• Hazelden CDP Clinical Administrators Guidebook
http://www.hazelden.org/OA_HTML/ibeCCtpItmDspRte.jsp?item=13480&sitex=10020:22372:US
Operational definitions for all of both the DDCAT and DDCMHT items, practical suggestions, examples, and actual tools for quality improvement
Mark McGovern Associate Professor
Department of Psychiatry Department of Community & Family Medicine
Dartmouth Medical School 2 Whipple Place, #202 Lebanon, NH 03766
(603) 381-1160 (603) 448-0129 FAX
http://dms.dartmouth.edu/prc/dual/atsr/ http://www.cooccurring.org/public/index.page